Argonaute RNA Ltd. is developing safe and reliable methods of temporarily silencing target genes in different tissue cells. Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. We show how our proprietary modification of small interfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. We use a novel method of stabilising the siRNA and thereby avoid a range of issues which have …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

169 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our mission is simple... bring innovative RNA modulating therapies to patients with severe, genetic neurological diseases. Vico Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. Vico is initially targeting spinocerebellar ataxia types 3 and 1 and Huntington’s disease. Our VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA. For more information, visit www.vicotx.com

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Mapping the druggable transcriptome An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Regulatory Medical Writing Your premium submission partner in bringing the right product, to the right patient, on time Accelerating Access to Treatments for Rare Diseases At the intersection of science and strategy, we support pharmaceutical companies, biotech, and CROs in bringing innovative therapies to market — especially in the challenging field of rare diseases. As a specialised regulatory medical writing and consulting agency, we provide expert guidance across the clinical development pathway. From early phase documentation to submissions for marketing authorisation, we turn complex science into meaningful communication that informs and inspires better healthcare decisions. With deep knowledge of regulatory …

71 similar entities Type: SMB Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Developing mRNA vaccines and therapeutics In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company. This acquisition further accelerates Sanofi’s efforts to develop transformative vaccines and therapies using mRNA technology. It adds a critical pillar to the company’s mRNA Center of Excellence, which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transcribing For Better Lives Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAheadTM, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Group's GalAheadTM mxRNA technology, is currently in Phase I development. STP125G is the second siRNA therapeutics …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

seRNA – enter the next level of mRNA technology It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets indications of highest medical need. Many devastating diseases cannot be effectively treated. Even if therapies exist, often they don’t specifically target the diseased area, leading to a high risk of severe side effects. To overcome this inherent problem, we have developed seRNA as a new RNA-based therapy approach.

59 similar entities Type: Startup Activities: deeptech biotech

a new wave of comfort and health. Wave Therapeutics, a Techstars company, has developed disruptive smart cushioning technology designed to prevent bedsores, save lives, and reduce a huge cost center for long-term and acute care facilities. Our devices help reduce the risks of bedsores and blood clots through a unique combination of tested medical therapies combined with powerful analytics capabilities. Using our technology healthcare facilities can reduce hospitalization stays and treatment costs, increase reimbursements, and eliminate crippling legal liabilities. Our technology is affordable, works better than anything else on the market, and has medical, consumer, and even military application with …

317 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Immunic (Nasdaq: IMUX) is a late-stage biotechnology company developing novel oral therapies for neurologic diseases. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. Privacy Policy: https://imux.com/privacy-policy/

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming drug discovery and materials research Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990 and is engaged with customers and collaborators in more than 70 countries. We welcome you to visit our blog at www.extrapolations.com. Stay Alert: Avoid Recruitment Scams Across industries, cybercriminals are posing as company recruiters using fake job postings …

58 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using …

240 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

H2020 project exploring safety, tolerability and clinical efficacy of solnatide IMP in COVID-19 patients. The SOLNATIDE project will clinically test the safety, tolerability and clinical efficacy of solnatide IMP in patients with severe COVID-19 requiring mechanical ventilation. APEPTICO’s lead-compound solnatide IMP has been designed for the therapeutic treatment of patients with Acute Respiratory Distress Syndrome (ARDS) and various forms of Pulmonary Oedema (PPO). Orally inhaled solnatide has delivered clinical proof-of-concept in one Phase I and two Phase IIa clinical studies (EUDRACT No. 2011-000223-33, 2012-001863-64 and 2013-000716-21). Currently, solnatide is subject to a Phase IIB trial (EUDRACT No. 2017-003855-47) being approved …

58 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A French liquid biopsy technology dedicated to the isolation of circulating tumor cells (CTCs) The number of cancer cases continues to rise worldwide, and detection is occurring earlier and earlier. In this context, precision medicine is no longer optional — it has become essential. Tailoring treatments to the specific characteristics of each patient is key to improving survival rates and quality of life. ScreenCell® is fully committed to this approach by developing single-use devices designed to isolate circulating tumor cells (CTCs) from a simple blood sample. Our liquid biopsy technology offers a non-invasive and cost-effective alternative for accessing valuable insights …

214 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

High Specificity Tools for RNAi, rRNA depletion & RNA Interactome Studies. Services: Making Sense of RNAi Screening Data We drive RNA research with tailored molecular tools. We are from Munich and provide researchers with highly complex & advanced genetic tools. Our core expertise is RNA interference, bioinformatics, and RNA research tools for RNA-Seq and Ribo-Seq. Distinguished by their exceptional targeting specificity and efficiency, our gene function analysis tools include - siPOOLTM for reliable gene silencing, raPOOLTM for targeted RNA affinity purification and riboPOOLTM for efficient ribosomal RNA depletion. Our technology combines high complexity oligo pooling (“Pack Hunter” approach), proprietary design …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

236 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments. Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused …

278 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotech specialized in the design of new medicine. Let's connect to know more about us ! At Aceso, we leverage our technology platform to explore new molecular pathways and develop strategic approaches aimed at redefining standards of care where existing therapies are insufficient. In the development of a new therapy for cystic fibrosis, Aceso is starting with ATC-101, its most advanced program designed to address the limitations of current treatments. Supported by robust proof-of-concept data and promising preclinical evidence, we are advancing toward IND-enabling studies, with entry into clinical trials as the next major milestone. With a science-driven roadmap and …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

FROM DISCOVERY TO THERAPEUTICS MT-act is a CNRS spin-off. #techtransfer We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the skeleton of the cells called microtubules - abbreviated MT. Stiffening of the skeleton of our cells is a central disease driver. That is why we act on them. We developed a technology platform to charter an entirely neglected pharmaceutical space. MT-act prioritizes indications based on scientific evidence, proven unmet medical needs and where the roadmap to patients is feasible and desired. Drug development, Microtubules, Tubulin code, Preclinical, Drug screening, first-in-class, and drug discovery

153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cellectis is developing life-changing product candidates to target and eradicate cancer cells. Cellectis is a global, clinical-stage biopharmaceutical company. As pioneers and innovators in our field, we are driven by a single mission: to develop breakthrough treatments for patients with unmet medical needs. With 26 years of expertise, we operate a best-in-class genome editing platform focused on immuno-oncology and gene therapy. By leveraging our proprietary gene-editing technologies, we engineer allogeneic CAR-T cells designed to recognize and eliminate cancer cells. Currently, our two lead clinical programs are evaluating therapies for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). As a …

173 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting the Source. Transforming the Outcome. We develop miRNA-based therapies that address the root causes of neurological diseases. This goes far beyond the limitations of current treatment options, which only manage individual symptoms.

157 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Theseus is developing best-in-class kinase inhibitors to shape the future of targeted oncology. Theseus Pharmaceuticals is passionately committed to outsmarting cancer resistance. Cancer is constantly mutating, allowing it to evade initially effective oncology treatments. Theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. Led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (TKIs), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology. PLEASE NOTE: All open positions for Theseus Pharmaceuticals will be …

55 similar entities Type: Startup Activities: it services Technologies: A.I. Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

443 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy

221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The CanVas platform is focused on developing novel cell therapies. The CanVas platform is spearheading the development of investigational allogeneic candidates for neurologic, rare and other serious diseases. Our world class team are dedicated to advancing a wave of investigational allogeneic products through excellence in translational research, clinical development and cell manufacturing. We are developing a pipeline of off-the-shelf cell therapies based on the pioneering Can-Vas platform. This could allow for the delivery of cell therapies to patients faster when they need it most and at greater scale. Our mission is to have a transformative impact on patients’ lives by …

245 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Making the promise of gene therapy a reality Nanogenics is a UK research based virtual biotechnology company. Founded to develop the LipTideTM nanoformulation platform, the focus now is on developing product ECP105 through preclinical and towards clinical testing. ECP105 is under development for the treatment of Glaucoma patients undergoing trabeculectomy surgery. This surgical technique relieves intra-ocular pressure by creating a channel into which the eye drains. Although well established and successful, surgical failure can occur if the surgical wound undergoes fibrosis and the scar prevents drainage. The active ingredient of ECP105 is an siRNA designed to down-regulate a gene involved …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

385 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Translating genetic discoveries into safe and effective treatments. Arctic Therapeutics is a clinical-stage biopharmaceutical company on a mission to treat and even prevent some of the world’s most pressing diseases by utilizing genetic sequencing to analyze and map the genetic causes of diseases at a granular level, applying our findings to develop effective treatments. Our company was founded by Dr. Hakon Hakonarson in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), which he launched in 2006 and established it as the largest pediatric biobank and genomic database in the world. We maintain close research relationships with …

368 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Decoding Metabolic Health with Explainable AI At MedInsights, we are dedicated to bringing optimized therapeutic options for patients suffering from metabolic, cardiometabolic, neurometabolic and rare diseases with high unmet needs. Our internal drug repositioning engine, NexusRx, serves as a cornerstone for our discovery research, employing internal sets of proprietary algorithms to detect unknown and unforeseen relationships between disease-targets-drugs. This opens up preclinical validation opportunities which we perform in close partnerships with our academic collaborators. We envision to perform clinical trials and bring therapeutics from lab to bed side. Crunchbase profile: https://www.crunchbase.com/organization/medinsights-0569 Biotech, Data Science, Healthcare, Computer Vision, Generative AI, Network …

525 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Data Analytics

Headquartered in Montreal, with a growing subsidiary in Charlotte, NC Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a patient-centric commercial-stage biopharmaceutical company dedicated to bringing innovative cardiology products to market. Our lead product, CARDAMYSTTM (etripamil), is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. We are also dedicated to the continued clinical investigation of etripamil as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR). At Milestone, everything we do is with the patient in mind. To learn more, visit www.milestonepharma.com. Thank you for your interest in Milestone Pharmaceuticals. …

61 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

293 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

270 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the broad potential of RNA medicines to transform human health We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, …

114 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable …

330 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bringing Precision Medicine to patients with Neurodevelopmental Disorders, including Autism Spectrum Disorder STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. Substance Use Disorder research: …

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease. AskBio’s gene therapy platform includes Pro10TM, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and …

225 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We power your science Sartorius Polyplus is a leading upstream solutions provider for advanced biological and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help customers (or the industry) optimize process economics while meeting strict scientific and regulatory standards. ​ ​ We wanted to share that we will not be actively posting or engaging on this LinkedIn account. …

114 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Addressing "undruggable"​ oncology targets by delivering whole antibodies inside the tumor and metastatic cells. Libera Bio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface, transmembrane or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins. << Fraud Alert for Potential Candidates >> At Libera Bio, your personal information and online safety are our top priorities. • Candidates should apply exclusively through our official webpage at https://www.liberabio.com/contact/ or rrhh@liberabio.com. • If …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster. Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process …

424 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

#BeyondBoundaries At Sygnature Discovery, a global drug discovery CRO, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible. We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment. Over the past 20 years, we’ve earned a track record of real impact: 60+ advanced candidates, 200+ patents filed, 200+ active projects. Over 90% of our customers choose to stay with us – from biotechs racing to clinic to pharma companies that …

271 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Exosome-based therapeutics Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‐CoV‐2 infection. Contact us at team@exogenus-t.com Biotechnology, Regenerative Medicine, Stem cells, exosomes, cell biology, and therapies

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. NateraTM is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San …

47 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Programmable Therapeutics for Causal Biology - Science Guides Us. The Genome Powers Us. Patients Ground Us. HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is …

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing our proprietary AxiomerTM RNA-editing platform technology Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary AxiomerTM RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/ RNA therapeutics, Drug development, Rare Diseases, Genetic Diseases, Orphan drugs, Pharmaceuticals, and RNA editing

174 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fueled by Connections to Transform Rare DiseasesTM Agios is a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with rare disease communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. Rooted in hematology, we combine deep biological expertise with real-world insights to advance a growing pipeline of medicines that reflect patients’ priorities. Our inclusive, collaborative culture sparks bold thinking and strengthens our connections – with each other and with the people we serve. Review our social media guidelines: https://www.agios.com/community-guidelines/ Biopharmaceuticals, Cellular Metabolism, and Rare …

312 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Unlocking the full potential of genetic medicines. At Nvelop, we are working to address the complex challenge of effectively delivering genetic medicines to target cells within the body (in vivo) in order to help treat patients with previously undruggable diseases. Our team is advancing two next-generation delivery platforms, started in the labs of our scientific co-founders Dr. David Liu of the Broad Institute of MIT and Harvard, and Dr. Keith Joung formerly of Mass General Hospital. We will use these platforms to build a pipeline of therapeutics internally and to enable strategic partners. We are building a culture and organization …

126 similar entities Type: Incubators & VCs Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mediar Therapeutics is a clinical stage company advancing first-in-class therapies to halt fibrosis progression. Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar’s goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach. For more information, contact …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the Power of Epigenetic Editing Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of disease. Epigenetics is nature’s central mechanism for gene regulation, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression. *Note: Be aware of fraudulent recruiting advertisements and scams: …

90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Genetic Medicine Delivered BreezeBio is a biotechnology company developing precision genetic medicines enabled by targeted, non-viral delivery across biologically relevant tissues. Using our proprietary NanoGalaxy® platform, we engineer nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types. Our platform has demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. We are advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology. Our lead program, BRZ-101, is designed to restore immune tolerance in type 1 diabetes and is advancing into IND-enabling studies. BreezeBio is headquartered in the South …

140 similar entities Type: Startup Activities: biotech deeptech nanotech Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

228 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering the Immune System to Transform Lives At Vir Biotechnology, Inc., we leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in chronic hepatitis delta are complemented by strategic programs in oncology. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients. Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the …

93 similar entities Type: Startup Activities: deeptech biotech Technologies: SaaS

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. We are dedicated to making a meaningful impact in patients’ lives as well as the communities where we live and work. Our team is guided by our core values of collaboration, accountability, passion, respect, and integrity. Insmed is headquartered in Bridgewater, NJ, and has offices and research locations throughout the United States, Europe, and Japan. We are proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as …

260 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Driving the next generation of endocrinology care. #acromegaly #crinetics #CarcinoidSyndrome We are a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine disease and endocrine-related tumors. Driven by the belief that no one should be defined by their disease, we’re transforming endocrine care to significantly improve the lives of patients, caregivers, and loved ones. As the premier, endocrine-rooted pharmaceutical company, we’re shaping the future of treatment, empowering individuals to live beyond their condition, and thrive. See our social media community guidelines here: https://crinetics.com/social-media-community-guidelines/ Notice of Fraudulent Activity for Job Applicants: Please be aware of …

69 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Translating condensate biology into medicine. Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. Please be aware of the potential for scams and fraudulent recruitment …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

634 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, Chemical process research, DMPK, and ADME

515 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers. oncology, cancer, biotechnology, immunotherapy, CAR T, and autoimmune

71 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Artificial Intelligence, High Performance Computing, and RNA sequencing data to find cures faster than ever before. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be …

Type: Startup Activities: biotech deeptech Technologies: A.I. - Deep Learning A.I. A.I. - Machine Learning

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital TherapeuticsTM, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such …

152 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: A.I. - Machine Learning

A messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A leader in liquid biopsy transforming the lives of cancer patients and their families. Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirstTM-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: SaaS

Designing and delivering cell therapies to transform the lives of people with cancer. Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Adaptimmune only accepts employment applications through our corporate website at Adaptimmune.com/Careers and through the ‘Easy Apply’ feature on …

59 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases. Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com. Biotech, Drug Development, Pharmaceuticals, and RNAi

110 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. …

437 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to the treatment of metabolic, fibrotic and inflammatory diseases Liminal BioSciences, through its wholly owned subsidary, Caledon Bioscience Inc., is a data-driven development-stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptor pathways (GPCRs). We are designing proprietary novel small molecule therapeutic candidates with the intent of developing best/first in class therapeutics for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs, using our drug discovery and medicinal chemistry expertise and deep understanding of GPCR biology. Our registered office is located in Belleville, Ontario and we …

169 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology